
Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.
Gilead Sciences, founded in 1987, is an American biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for critical diseases. The company's core mission is to advance the care of patients suffering from life-threatening illnesses such as HIV, cancer, and inflammatory conditions. Gilead's product portfolio includes antiviral drugs, oncology treatments, and anti-inflammatory medications, with a strong focus on scientific innovation and health equity.
Notable figures associated with Gilead Sciences include its founder Michael L. Riordan and key investors such as BlackRock and Vanguard Group. The company has achieved significant milestones, including the development of groundbreaking antiviral therapies like Remdesivir for COVID-19 treatment. Gilead's impact is profound, having transformed the landscape of antiviral treatment and improved access to essential medicines globally.
Bristol Myers Squibb
bms.com

Genentech
gene.com

GSK
gsk.com

Rigel Pharmaceuticals
rigel.com

Ionis Pharmaceuticals
ionispharma.com

Intercept Pharmaceuticals

AstraZeneca
astrazeneca.com
Biogen
biogen.com

Kyntra Bio
fibrogen.com
AbbVie
abbvie.com
Regeneron Ph
regeneron.com
Vertex Pharmaceuticals
vrtx.com

G1 Therapeutics
g1therapeutics.com

Enanta Pharmaceuticals
enanta.com
Altiris Therapeutics
Companies similar to Gilead Sciences include Bristol Myers Squibb, Genentech, GSK and Rigel Pharmaceuticals.
Gilead Sciences was founded in 1987.
Gilead Sciences' headquarters is located in Foster City, CA, US.
Gilead Sciences' most recent funding round was for $2B (USD) in September 2023.
As of Sep 7, 2023, Gilead Sciences has raised a total of $2B (USD).
Gilead Sciences has 17,000 employees as of Feb 6, 2024.